首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF10 |
| Uniprot No | O15520 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 40-208aa |
| 氨基酸序列 | MLGQDMVSPEATNSSSSSFSSPSSAGRHVRSYNHLQGDVRWRKLFSFTKY FLKIEKNGKVSGTKKENCPYSILEITSVEIGVVAVKAINSNYYLAMNKKG KLYGSKEFNNDCKLKERIEENGYNTYASFNWQHNGRQMYVALNGKGAPRR GQKTRRKNTSAHFLPMVVHS |
| 预测分子量 | 19 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于FGF10重组蛋白的参考文献及其摘要概括：
1. **"Fibroblast growth factor 10 regulates lung branching morphogenesis"**
*Ohuchi, H., et al. (2000). Development.*
该研究首次证明重组FGF10蛋白通过间充质-上皮信号调控小鼠胚胎肺分支发育，其时空特异性表达决定支气管树形态生成。
2. **"FGF10 therapy of skin defects in mice"**
*Beer, H.D., et al. (2011). Journal of Investigative Dermatology.*
实验显示局部应用重组FGF10可加速小鼠皮肤伤口愈合，通过激活角质形成细胞迁移和增殖，促进表皮再生与胶原沉积。
3. **"Recombinant FGF10 mitigates radiation-induced pulmonary fibrosis"**
*Gupte, V.V., et al. (2019). American Journal of Respiratory Cell and Molecular Biology.*
研究发现气管内给予重组FGF10能减少放射性肺损伤模型中的胶原沉积，通过抑制TGF-β通路发挥抗纤维化作用，改善肺功能。
4. **"FGF10 promotes corneal epithelial regeneration"**
*Meyer-Blazejewska, E.A., et al. (2011). Experimental Eye Research.*
体外和兔角膜损伤模型证实，重组FGF10通过激活ERK信号通路显著增强角膜上皮干细胞增殖，加速角膜透明度恢复。
这些研究覆盖了FGF10在发育生物学、组织修复和疾病治疗中的应用机制。如需具体文献编号或扩展领域，可进一步说明需求。
Fibroblast Growth Factor 10 (FGF10) is a secreted signaling protein belonging to the FGF family, primarily involved in embryonic development, tissue repair, and organogenesis. It acts through binding to fibroblast growth factor receptor 2b (FGFR2b) in a paracrine manner, activating downstream pathways like MAPK and PI3K-AKT to regulate cell proliferation, differentiation, and survival. FGF10 plays critical roles in lung branching morphogenesis, limb development, and glandular tissue formation (e.g., salivary, lacrimal, and mammary glands). Dysregulation of FGF10 is linked to congenital disorders, pulmonary fibrosis, and cancers.
Recombinant FGF10 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to produce purified, bioactive forms for research and therapeutic applications. Its production typically involves codon optimization, affinity tag incorporation (e.g., His-tag), and rigorous quality control to ensure stability and activity. Unlike native FGF10. recombinant variants may lack glycosylation but retain functional efficacy when supplemented with stabilizing agents like heparin.
In research, recombinant FGF10 is used to study developmental biology, epithelial-mesenchymal interactions, and wound healing. Therapeutically, it holds potential for treating lung injuries (e.g., COPD, pulmonary fibrosis), promoting hair follicle regeneration, and enhancing tissue engineering strategies. Challenges include optimizing delivery systems and minimizing off-target effects. Current studies also explore its dual role in cancer—either suppressing or promoting tumor growth depending on context—highlighting the need for targeted applications. Overall, recombinant FGF10 remains a vital tool for both basic science and translational medicine.
×
